
Aizen Therapeutics is a biotechnology company pioneering the development of Mirror Peptides, a novel class of synthetic, fully D-amino acid peptides that offer superior therapeutic stability and reduced immunogenicity compared to natural peptides. Their proprietary DaX™ platform, leveraging generative AI and advanced computational models, enables rapid design-build-test cycles (~4 weeks) with high hit rates for drug development targeting neurological disorders, oncology, and genetic diseases. This platform enhances drug specificity, half-life, and solubility, positioning Aizen as a leader in next-generation peptide therapeutics with a focus on improving patient safety and efficacy.

Aizen Therapeutics is a biotechnology company pioneering the development of Mirror Peptides, a novel class of synthetic, fully D-amino acid peptides that offer superior therapeutic stability and reduced immunogenicity compared to natural peptides. Their proprietary DaX™ platform, leveraging generative AI and advanced computational models, enables rapid design-build-test cycles (~4 weeks) with high hit rates for drug development targeting neurological disorders, oncology, and genetic diseases. This platform enhances drug specificity, half-life, and solubility, positioning Aizen as a leader in next-generation peptide therapeutics with a focus on improving patient safety and efficacy.
Founded: 2022 (Caltech spinout)
Headquarters: San Diego, CA
Core technology: DaX™ generative AI platform for D‑amino‑acid (Mirror) peptides
Therapeutic focus: Neurological disorders, oncology, genetic diseases; oral biologics
Recent financing: $13.0M seed (Nov 2024)
| Company |
|---|
Designing next‑generation peptide therapeutics that overcome limitations of natural peptides (stability, immunogenicity, oral delivery).
2022
Biotechnology
$13,000,000
Round announced November 2024 with participation from Wilson Hill Ventures and Cercano Management.
“Madrona Venture Group led seed; participation from Wilson Hill Ventures and Cercano Management”
Title
: Principal Scientist, Molecular Modeling/Peptide Design
The Role
The Principal Scientist will design modern oral peptides including D-peptide therapeutics, driving structure-activity relationships (SAR) from hit identification through clinical candidate nomination. Using molecular modeling and computational tools and experimental data, you will advance early hits by optimizing novel D-amino acid peptides with drug-like properties, while collaborating across a multidisciplinary team to translate scientific discoveries into transformative medicines. We are looking for an outstanding Molecular Modeller with strong peptide/medicinal chemistry skills or an outstanding Peptide/Medicinal Chemist with strong Molecular Modeling skills.
Our Ideal Candidate
You are passionate about the company's mission and a self-starter with an inextinguishable fire to compete and succeed. You thrive in an environment that requires crisp judgment, pragmatic decision-making, rapid course-corrections, and comfort with market ambiguity. You discharge your duties within a culture of mutual team respect, high performance, humility, and humor.
Key responsibilities
Candidate Skills and Experience
About Aizen
Aizen is an AI-driven biotechnology company pioneering Mirror Peptides, a novel class of biologic medicines. Mirror Peptides are synthetic, fully D-amino acid peptides that represent a vast, unexplored therapeutic chemical space. Backed by life science venture capital and based in the biotech hub of San Diego, CA. A video summary of the founder story is here.
Location & Compensation: